Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes.
Chong C, Müller M, Pak H, Harnett D, Huber F, Grun D, Leleu M, Auger A, Arnaud M, Stevenson BJ, Michaux J, Bilic I, Hirsekorn A, Calviello L, Simó-Riudalbas L, Planet E, Lubiński J, Bryśkiewicz M, Wiznerowicz M, Xenarios I, Zhang L, Trono D, Harari A, Ohler U, Coukos G, Bassani-Sternberg M. Chong C, et al. Among authors: auger a. Nat Commun. 2020 Mar 10;11(1):1293. doi: 10.1038/s41467-020-14968-9. Nat Commun. 2020. PMID: 32157095 Free PMC article.
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A, Hottinger A, Wolf B, Navarro Rodrigo B, Ochoa de Olza M, Auger A, Kuntzer T, Comte D, Zimmer V, Gannon P, Kandalaft L, Michielin O, Zimmermann S, Harari A, Trueb L, Coukos G. Orcurto A, et al. Among authors: auger a. J Immunother Cancer. 2020 Aug;8(2):e001155. doi: 10.1136/jitc-2020-001155. J Immunother Cancer. 2020. PMID: 32847987 Free PMC article.
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, Murgues C, Zangiacomi V, Rubin O, Ellefsen Lavoie K, Guillemot L, Navarro Rodrigo B, Nguyen-Ngoc T, Rusakiewicz S, Rossier L, Boudousquié C, Baumgaertner P, Zimmermann S, Trueb L, Iancu EM, Sempoux C, Demartines N, Coukos G, Kandalaft LE. Gannon PO, et al. Among authors: auger a. Cytotherapy. 2020 Dec;22(12):780-791. doi: 10.1016/j.jcyt.2020.07.011. Epub 2020 Oct 14. Cytotherapy. 2020. PMID: 33069566
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R, Bobisse S, Chiffelle J, Arnaud M, Petremand R, Queiroz L, Michel A, Reichenbach P, Cesbron J, Auger A, Baumgaertner P, Guillaume P, Schmidt J, Irving M, Kandalaft LE, Speiser DE, Coukos G, Harari A. Genolet R, et al. Among authors: auger a. Cell Rep Methods. 2023 Apr 24;3(4):100459. doi: 10.1016/j.crmeth.2023.100459. eCollection 2023 Apr 24. Cell Rep Methods. 2023. PMID: 37159666 Free PMC article.
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M, Huber F, Arnaud M, Kraemer AI, Altimiras ER, Michaux J, Taillandier-Coindard M, Chiffelle J, Murgues B, Gehret T, Auger A, Stevenson BJ, Coukos G, Harari A, Bassani-Sternberg M. Müller M, et al. Among authors: auger a. Immunity. 2023 Nov 14;56(11):2650-2663.e6. doi: 10.1016/j.immuni.2023.09.002. Epub 2023 Oct 9. Immunity. 2023. PMID: 37816353 Free article.
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: auger a. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, Bobisse S, Chiffelle J, Gehert T, Müller M, Pak H, Krämer AI, Altimiras ER, Racle J, Taillandier-Coindard M, Muehlethaler K, Auger A, Saugy D, Murgues B, Benyagoub A, Gfeller D, Laniti DD, Kandalaft L, Rodrigo BN, Bouchaab H, Tissot S, Coukos G, Harari A, Bassani-Sternberg M. Huber F, et al. Among authors: auger a. Nat Biotechnol. 2024 Oct 11. doi: 10.1038/s41587-024-02420-y. Online ahead of print. Nat Biotechnol. 2024. PMID: 39394480
Nudge theory and gambling: a scoping review.
Fortier MÈ, Audette-Chapdelaine S, Auger AM, Brodeur M. Fortier MÈ, et al. Among authors: auger am. Front Public Health. 2024 Jun 10;12:1377183. doi: 10.3389/fpubh.2024.1377183. eCollection 2024. Front Public Health. 2024. PMID: 38915754 Free PMC article. Review.
151 results